Literature DB >> 32564084

Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study.

Chuan-Bing Cheng1, Qu-Xia Zhang2, Lv-Ping Zhuang2, Jian-Wei Sun3.   

Abstract

OBJECTIVE: The immune inflammation-based score is recognized as a prognostic marker for cancer. However, the most accurate prognostic marker for patients with gastric cancer remains undetermined. We aimed to evaluate the predictive value of the lymphocyte-to-C-reactive protein ratio for outcomes in gastric cancer patients after radical gastrectomy.
METHODS: A total of 607 gastric cancer patients treated at three Chinese institutions were included. Receiver operating characteristic curves were generated, and the areas under the curve were calculated to compare the predictive value among the inflammation-based score, lymphocyte-to-C-reactive protein ratio, C-reactive protein/albumin and neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios. Cox regression was performed to determine the prognostic factors for overall survival.
RESULTS: The median follow-up time was 63 months (range: 1-84 months). The optimal cut-off value for lymphocyte-to-C-reactive protein ratio was 0.63. The patients were divided into the LCR <0.63 (LLCR, n = 294) group and the LCR ≥0.63 (HLCR, n = 313) group. LLCR was significantly correlated with poor clinical characteristics. Compared with inflammation-based score, lymphocyte-to-C-reactive protein ratio had the highest areas under the curve (0.695). Patients with LLCR experienced more post-operative complications than the HLCR group (20.4 vs. 12.1%, P = 0.006). Multivariate analysis showed that a higher lymphocyte-to-C-reactive protein ratio (HR: 0.545, 95%CI: 0.372-0.799, P = 0.002) was associated with better overall survival. The HLCR group had higher 5-year overall survival rate than the LLCR group (80.5 vs. 54.9%, P < 0.001).
CONCLUSIONS: Preoperative lymphocyte-to-C-reactive protein ratio levels can effectively predict the short-term and oncological efficacy of gastric cancer patients after radical gastrectomy with a predictive value significantly better than other inflammation-based score.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Entities:  

Keywords:  complication; gastric cancer; immune inflammation-based score; lymphocyte-c-reactive protein ratio; prognosis

Year:  2020        PMID: 32564084     DOI: 10.1093/jjco/hyaa099

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  14 in total

1.  The Association of the Lymphocyte-to-C-Reactive-Protein Ratio With Gastric Cancer Patients Who Receive Curative Treatment.

Authors:  Toru Aoyama; Masato Nakazano; Shinsuke Nagasawa; Kentaro Hara; Keisuke Komori; Hiroshi Tamagawa; Yukio Maezawa; Kenki Segami; Kazuki Kano; Takashi Ogata; Norio Yukawa; Yasushi Rino; Takashi Oshima
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Preoperative nutrition and exercise intervention in frailty patients with gastric cancer undergoing gastrectomy.

Authors:  Yuma Wada; Masaaki Nishi; Kozo Yoshikawa; Chie Takasu; Takuya Tokunaga; Toshihiro Nakao; Hideya Kashihara; Toshiaki Yoshimoto; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2022-06-30       Impact factor: 3.850

3.  Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer.

Authors:  Yuma Wada; Masaaki Nishi; Kozo Yoshikawa; Chie Takasu; Takuya Tokunaga; Toshihiro Nakao; Hideya Kashihara; Toshiaki Yoshimoto; Mitsuo Shimada
Journal:  Oncol Lett       Date:  2022-09-28       Impact factor: 3.111

4.  Peking prognostic score is a useful prognostic factor in patients with gastric cancer liver metastases receiving hepatectomy.

Authors:  Jianping Xiong; Yunzi Wu; Haitao Hu; Wenzhe Kang; Yang Li; Peng Jin; Xinxin Shao; Weikun Li; Yibin Xie; Yantao Tian
Journal:  Front Nutr       Date:  2022-09-30

5.  Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer.

Authors:  He-Yang Zhang; Hai-Lun Xie; Guo-Tian Ruan; Qi Zhang; Yi-Zhong Ge; Xiao-Yue Liu; Meng Tang; Meng-Meng Song; Shi-Qi Lin; Ming Yang; Xiao-Wei Zhang; Hong-Xia Xu; Chun-Hua Song; Han-Ping Shi
Journal:  BMC Cancer       Date:  2022-10-20       Impact factor: 4.638

6.  Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.

Authors:  Norifumi Iseda; Shinji Itoh; Tomoharu Yoshizumi; Takahiro Tomiyama; Akinari Morinaga; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Takeo Toshima; Yoshihiro Nagao; Noboru Harada; Yoshinao Oda; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2021-07-12       Impact factor: 3.402

7.  Prognostic Significance of Preoperative Lymphocyte-to-C-Reactive Protein Ratio in Patients with Non-Metastatic Colorectal Cancer.

Authors:  Wenting Ou; Caijin Zhou; Xiaoqing Zhu; Lin Lin; Qingwen Xu
Journal:  Onco Targets Ther       Date:  2021-01-12       Impact factor: 4.147

8.  PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer.

Authors:  Fang Wang; Xiaoting Wu; Yajun Li; Xiangmei Cao; Cao Zhang; Yujing Gao
Journal:  Oncol Lett       Date:  2021-02-17       Impact factor: 2.967

9.  Prognostic Value of the Preoperative Lymphocyte-to-C-Reactive Protein Ratio and Albumin-to-Globulin Ratio in Patients with Osteosarcoma.

Authors:  Hongzhi Hu; Xiangtian Deng; Qingcheng Song; Hongzhi Lv; Wei Chen; Xin Xing; Jian Zhu; Zhanchao Tan; Xiaodong Cheng; Baichuan Wang; Zengwu Shao; Yingze Zhang
Journal:  Onco Targets Ther       Date:  2020-12-09       Impact factor: 4.147

10.  Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio-EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy.

Authors:  Zhang-Zan Huang; Wen Wen; Xin Hua; Chen-Ge Song; Xi-Wen Bi; Jia-Jia Huang; Wen Xia; Zhong-Yu Yuan
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.